sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Alcohol: Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.
|
Alcohol
|
vardenafil
|
NONE
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s38
|
DDI-DrugBank.d198.s38.p1
|
Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.
|
Rifampin
|
norethindrone
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s36
|
DDI-DrugBank.d485.s36.p6
|
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
|
benzodiazepines
|
diltiazem
|
NONE
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s8
|
DDI-DrugBank.d131.s8.p52
|
All vasopressors should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors.
|
vasopressors
|
monoamine oxidase (MAO) inhibitors
|
ADVISE
|
Epinephrine_ddi.xml
|
DDI-DrugBank.d247.s1
|
DDI-DrugBank.d247.s1.p0
|
Absorption of tetracycline is impaired by bismuth subsalicylate.
|
tetracycline
|
bismuth subsalicylate
|
MECHANISM
|
Doxycycline_ddi.xml
|
DDI-DrugBank.d500.s3
|
DDI-DrugBank.d500.s3.p0
|
Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.
|
Folic acid
|
phenobarbital
|
EFFECT
|
Leucovorin_ddi.xml
|
DDI-DrugBank.d151.s0
|
DDI-DrugBank.d151.s0.p0
|
Because dexfenfluramine is a serotonin releaser and reuptake inhibitor, dexfenfluramine should not be used concomitantly with a MAO inhibitor.
|
dexfenfluramine
|
MAO inhibitor
|
ADVISE
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s1
|
DDI-DrugBank.d423.s1.p2
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
DURAGESIC
|
central nervous system depressants
|
EFFECT
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p13
|
Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
|
Aprepitant
|
ritonavir
|
ADVISE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s31
|
DDI-DrugBank.d382.s31.p5
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
clofibrate
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p18
|
Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs.
|
glutethimide
|
coumarin drugs
|
ADVISE
|
1109248.xml
|
DDI-MedLine.d106.s6
|
DDI-MedLine.d106.s6.p2
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
allopurinol
|
dextrothyroxine
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p119
|
Thus in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with antithrombin III (human).
|
heparin
|
antithrombin III
|
ADVISE
|
Heparin_ddi.xml
|
DDI-DrugBank.d488.s4
|
DDI-DrugBank.d488.s4.p0
|
In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.
|
metformin
|
dofetilide
|
ADVISE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s22
|
DDI-DrugBank.d558.s22.p4
|
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
|
alprazolam
|
benzodiazepines
|
NONE
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s8
|
DDI-DrugBank.d131.s8.p13
|
Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;
|
Amphetamines
|
phenobarbital
|
MECHANISM
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s23
|
DDI-DrugBank.d236.s23.p2
|
Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).
|
enalapril
|
antihypertensive agents
|
EFFECT
|
Enalapril_ddi.xml
|
DDI-DrugBank.d107.s3
|
DDI-DrugBank.d107.s3.p3
|
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.
|
procainamide
|
amiodarone
|
NONE
|
Amiodarone_ddi.xml
|
DDI-DrugBank.d143.s27
|
DDI-DrugBank.d143.s27.p17
|
Drugs that may have their plasma concentration altered by dasatinib CYP3A4 Substrates: Dasatinib is a time-dependent inhibitor of CYP3A4.
|
dasatinib
|
Dasatinib
|
NONE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s14
|
DDI-DrugBank.d48.s14.p0
|
It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.
|
Vardenafil
|
indinavir
|
ADVISE
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s11
|
DDI-DrugBank.d198.s11.p0
|
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.
|
barbiturates
|
corticosteroids
|
MECHANISM
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s18
|
DDI-DrugBank.d314.s18.p3
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
loratadine
|
troleandomycin
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p292
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
amiodarone
|
triazolam
|
NONE
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p68
|
Anticoagulant inhibition was observed during the administration of phenobarbital, secobarbital and glutethimide;
|
secobarbital
|
glutethimide
|
NONE
|
1109248.xml
|
DDI-MedLine.d106.s4
|
DDI-MedLine.d106.s4.p2
|
A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.
|
cimetidine
|
diltiazem
|
MECHANISM
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s12
|
DDI-DrugBank.d565.s12.p2
|
therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine.
|
nelfinavir
|
didanosine
|
ADVISE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s26
|
DDI-DrugBank.d340.s26.p0
|
Anticoagulants: Flurbiprofen like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.
|
Flurbiprofen
|
anti-coagulants
|
EFFECT
|
Flurbiprofen_ddi.xml
|
DDI-DrugBank.d529.s2
|
DDI-DrugBank.d529.s2.p4
|
Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.
|
Isoflurane
|
enflurane
|
NONE
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s3
|
DDI-DrugBank.d267.s3.p0
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
alfentanyl
|
saquinavir
|
MECHANISM
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p132
|
If a diuretic is also used, it may increase the risk of lithium toxicity.
|
diuretic
|
lithium
|
EFFECT
|
Captopril_ddi.xml
|
DDI-DrugBank.d175.s20
|
DDI-DrugBank.d175.s20.p0
|
aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone.
|
nevirapine
|
methadone
|
EFFECT
|
Nevirapine_ddi.xml
|
DDI-DrugBank.d270.s58
|
DDI-DrugBank.d270.s58.p0
|
Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
|
SPRYCEL
|
saquinavir
|
MECHANISM
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s1
|
DDI-DrugBank.d48.s1.p9
|
The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
|
phenothiazine derivatives
|
thyroid hormones
|
NONE
|
Insulin Glargine recombinant_ddi.xml
|
DDI-DrugBank.d527.s2
|
DDI-DrugBank.d527.s2.p91
|
Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
|
erythromycin
|
dihydroergotamine
|
EFFECT
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s23
|
DDI-DrugBank.d522.s23.p4
|
Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2.
|
grepafloxacin
|
theophylline
|
MECHANISM
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s11
|
DDI-DrugBank.d78.s11.p5
|
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
|
terfenadine
|
Antimycobacterial agents
|
NONE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s6
|
DDI-DrugBank.d340.s6.p64
|
Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.
|
iron
|
ranitidine
|
NONE
|
Anagrelide_ddi.xml
|
DDI-DrugBank.d75.s2
|
DDI-DrugBank.d75.s2.p22
|
Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.
|
dirithromycin
|
antacids
|
MECHANISM
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s15
|
DDI-DrugBank.d522.s15.p9
|
Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
|
Antihistamines
|
sedatives
|
EFFECT
|
Cyproheptadine_ddi.xml
|
DDI-DrugBank.d492.s1
|
DDI-DrugBank.d492.s1.p3
|
Fluconazole, and the 5-HT3 antiemetics ondansetron (Zofran) and granisetron (Kytril) have all been used with BUSULFEX.
|
Fluconazole
|
Zofran
|
NONE
|
Busulfan_ddi.xml
|
DDI-DrugBank.d72.s1
|
DDI-DrugBank.d72.s1.p2
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
carbamazepine
|
sildenafil
|
NONE
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p36
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Tegretol
|
vitamin C
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p394
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
allopurinol
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1
|
Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.
|
butorphanol
|
barbiturates
|
EFFECT
|
Butorphanol_ddi.xml
|
DDI-DrugBank.d246.s0
|
DDI-DrugBank.d246.s0.p2
|
Patients who are treated with ZYVOX and concomitant serotonergic agents should be closely observed for signs and symptoms of serotonin syndrome (e.g., cognitive dysfunction, hyperpyrexia, hyperreflexia, incoordination).
|
ZYVOX
|
serotonergic agents
|
EFFECT
|
Linezolid_ddi.xml
|
DDI-DrugBank.d441.s7
|
DDI-DrugBank.d441.s7.p0
|
Inhibitors of CYP2D6: Because CYP2D6 is involved in duloxetine metabolism, concomitant use of duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of duloxetine.
|
duloxetine
|
duloxetine
|
NONE
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s3
|
DDI-DrugBank.d548.s3.p1
|
Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.
|
apraclonidine
|
beta-blockers
|
ADVISE
|
Apraclonidine_ddi.xml
|
DDI-DrugBank.d224.s8
|
DDI-DrugBank.d224.s8.p0
|
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.
|
Cephalosporins
|
cefazolin
|
NONE
|
Menadione_ddi.xml
|
DDI-DrugBank.d139.s1
|
DDI-DrugBank.d139.s1.p12
|
Antacid: When atorvastatin and Maalox TC suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.
|
atorvastatin
|
Maalox TC
|
MECHANISM
|
Atorvastatin_ddi.xml
|
DDI-DrugBank.d140.s1
|
DDI-DrugBank.d140.s1.p3
|
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine.
|
trovafloxacin
|
morphine
|
MECHANISM
|
11210403.xml
|
DDI-MedLine.d124.s1
|
DDI-MedLine.d124.s1.p2
|
Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
|
Cholestyramine
|
phenobarbital
|
MECHANISM
|
Cholestyramine_ddi.xml
|
DDI-DrugBank.d566.s0
|
DDI-DrugBank.d566.s0.p7
|
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
|
butyrophenones
|
APOKYN
|
EFFECT
|
Apomorphine_ddi.xml
|
DDI-DrugBank.d357.s3
|
DDI-DrugBank.d357.s3.p41
|
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.
|
itraconazole
|
almotriptan
|
ADVISE
|
Almotriptan_ddi.xml
|
DDI-DrugBank.d299.s11
|
DDI-DrugBank.d299.s11.p8
|
Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.
|
triazolam
|
tiagabine
|
ADVISE
|
Tiagabine_ddi.xml
|
DDI-DrugBank.d277.s23
|
DDI-DrugBank.d277.s23.p2
|
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
|
TRACRIUM
|
magnesium
|
EFFECT
|
Atracurium_ddi.xml
|
DDI-DrugBank.d469.s7
|
DDI-DrugBank.d469.s7.p7
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
itraconazole
|
contraceptives
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p743
|
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
|
Flupenthixol
|
Tricyclic antidepressants
|
EFFECT
|
Flupenthixol_ddi.xml
|
DDI-DrugBank.d13.s0
|
DDI-DrugBank.d13.s0.p65
|
If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.
|
anticholinesterase agents
|
corticosteroid
|
ADVISE
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s5
|
DDI-DrugBank.d314.s5.p0
|
Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.
|
amphetamines
|
acidifying agents
|
MECHANISM
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s21
|
DDI-DrugBank.d236.s21.p3
|
When sympathomimetic drugs are given to patients receiving monoamine oxidase inhibitors, hypertensive reactions, including hypertensive crises, may occur.
|
sympathomimetic drugs
|
monoamine oxidase inhibitors
|
EFFECT
|
Azatadine_ddi.xml
|
DDI-DrugBank.d448.s2
|
DDI-DrugBank.d448.s2.p0
|
Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.
|
b-lactam antibiotics
|
probenecid
|
MECHANISM
|
Loracarbef_ddi.xml
|
DDI-DrugBank.d351.s0
|
DDI-DrugBank.d351.s0.p5
|
In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.
|
isoflurane
|
NIMBEX
|
ADVISE
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s9
|
DDI-DrugBank.d60.s9.p2
|
Increased toxicity (CNS depression): CNS depressants, MAO inhibitors, tricyclic antidepressants, phenothiazines.
|
CNS depressants
|
tricyclic antidepressants
|
NONE
|
Chlorpheniramine_ddi.xml
|
DDI-DrugBank.d235.s2
|
DDI-DrugBank.d235.s2.p1
|
Special consideration should be given to the administration of ETHYOL in patients receiving antihypertensive medications or other drugs that could cause or potentiate hypotension.
|
ETHYOL
|
antihypertensive medications
|
ADVISE
|
Amifostine_ddi.xml
|
DDI-DrugBank.d563.s0
|
DDI-DrugBank.d563.s0.p0
|
These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.
|
digoxin
|
amiodarone
|
MECHANISM
|
3964797.xml
|
DDI-MedLine.d61.s9
|
DDI-MedLine.d61.s9.p0
|
DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.
|
DOSTINEX
|
butyrophenones
|
ADVISE
|
Cabergoline_ddi.xml
|
DDI-DrugBank.d282.s0
|
DDI-DrugBank.d282.s0.p1
|
The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;
|
penicillin G
|
colestipol hydrochloride
|
MECHANISM
|
Colestipol_ddi.xml
|
DDI-DrugBank.d345.s11
|
DDI-DrugBank.d345.s11.p11
|
When you are using idoxuridine, it is especially important that your health care professional know if you are using the following: Eye product containing boric acid.
|
idoxuridine
|
boric acid
|
ADVISE
|
Idoxuridine_ddi.xml
|
DDI-DrugBank.d91.s2
|
DDI-DrugBank.d91.s2.p0
|
Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.
|
Clozapine
|
carbamazepine
|
ADVISE
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s18
|
DDI-DrugBank.d480.s18.p0
|
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
|
apomorphine
|
granisetron
|
NONE
|
Apomorphine_ddi.xml
|
DDI-DrugBank.d357.s0
|
DDI-DrugBank.d357.s0.p13
|
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).
|
Gleevec
|
itraconazole
|
ADVISE
|
Imatinib_ddi.xml
|
DDI-DrugBank.d115.s0
|
DDI-DrugBank.d115.s0.p12
|
Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of interferon-alfa and PROLEUKIN, including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.
|
interferon-alfa
|
PROLEUKIN
|
EFFECT
|
Aldesleukin_ddi.xml
|
DDI-DrugBank.d114.s9
|
DDI-DrugBank.d114.s9.p0
|
There have been reports of theophylline-related side effects in patients on concomitant therapy with norfloxacin and theophylline.
|
norfloxacin
|
theophylline
|
EFFECT
|
Norfloxacin_ddi.xml
|
DDI-DrugBank.d217.s1
|
DDI-DrugBank.d217.s1.p2
|
Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.
|
Intestinal adsorbents
|
Acarbose
|
MECHANISM
|
Acarbose_ddi.xml
|
DDI-DrugBank.d536.s4
|
DDI-DrugBank.d536.s4.p4
|
Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.
|
interleukin-2
|
radiographic iodinated contrast media
|
EFFECT
|
Aldesleukin_ddi.xml
|
DDI-DrugBank.d114.s11
|
DDI-DrugBank.d114.s11.p2
|
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.
|
magnesium
|
magnesium
|
NONE
|
7786695.xml
|
DDI-MedLine.d103.s3
|
DDI-MedLine.d103.s3.p5
|
Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
|
chlorprothixene
|
antiparkinsonian agents
|
ADVISE
|
Chlorprothixene_ddi.xml
|
DDI-DrugBank.d503.s7
|
DDI-DrugBank.d503.s7.p2
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Dilantin
|
antifungals
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p292
|
(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.
|
Femara
|
tamoxifen
|
MECHANISM
|
Letrozole_ddi.xml
|
DDI-DrugBank.d157.s1
|
DDI-DrugBank.d157.s1.p0
|
In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.
|
ethionamide
|
cycloserine
|
EFFECT
|
Ethionamide_ddi.xml
|
DDI-DrugBank.d166.s2
|
DDI-DrugBank.d166.s2.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
theophylline
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p36
|
Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
|
didanosine
|
lomefloxacin
|
MECHANISM
|
Lomefloxacin_ddi.xml
|
DDI-DrugBank.d516.s3
|
DDI-DrugBank.d516.s3.p35
|
Conversely, the coumarin anticoagulants have been reported to increase the serum levels and prolong the serum half-life of phenytoin by inhibiting its metabolism.
|
coumarin anticoagulants
|
phenytoin
|
MECHANISM
|
Ethotoin_ddi.xml
|
DDI-DrugBank.d359.s4
|
DDI-DrugBank.d359.s4.p0
|
Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied
|
Antizol
|
carbamazepine
|
MECHANISM
|
Fomepizole_ddi.xml
|
DDI-DrugBank.d228.s2
|
DDI-DrugBank.d228.s2.p1
|
- a steroid medicine such as prednisone (Deltasone, Orasone, others), methylprednisolone (Medrol, others), prednisolone (Prelone, Pediapred, others), and others;
|
steroid medicine
|
prednisolone
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s7
|
DDI-DrugBank.d521.s7.p5
|
Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
|
alfentanil
|
fentanyl
|
NONE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s15
|
DDI-DrugBank.d48.s15.p4
|
Therefore, when EDECRIN and non- steroidal anti- inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
|
EDECRIN
|
non- steroidal anti- inflammatory agents
|
EFFECT
|
Ethacrynic acid_ddi.xml
|
DDI-DrugBank.d414.s7
|
DDI-DrugBank.d414.s7.p0
|
Similarly, ethanol decreased the rate of elimination of Antizol (by approximately 50%) by the same mechanism.
|
ethanol
|
Antizol
|
MECHANISM
|
Fomepizole_ddi.xml
|
DDI-DrugBank.d228.s1
|
DDI-DrugBank.d228.s1.p0
|
Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
|
guanethidine
|
antihistamines
|
NONE
|
Chlorpromazine_ddi.xml
|
DDI-DrugBank.d86.s1
|
DDI-DrugBank.d86.s1.p75
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
danazol
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p5
|
the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine.
|
naloxone
|
morphine
|
EFFECT
|
3968644.xml
|
DDI-MedLine.d30.s9
|
DDI-MedLine.d30.s9.p1
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
fenoprofen
|
sulfamethoxazole
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p922
|
Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.
|
aminoglycosides
|
MAXIPIME
|
ADVISE
|
Cefepime_ddi.xml
|
DDI-DrugBank.d378.s0
|
DDI-DrugBank.d378.s0.p0
|
International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy.
|
warfarin
|
IRESSA
|
EFFECT
|
Gefitinib_ddi.xml
|
DDI-DrugBank.d207.s2
|
DDI-DrugBank.d207.s2.p0
|
Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or thiazolesulfone.
|
PAH
|
sulfonamides
|
EFFECT
|
Aminohippurate_ddi.xml
|
DDI-DrugBank.d416.s0
|
DDI-DrugBank.d416.s0.p0
|
Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.
|
cephalexin
|
metformin
|
ADVISE
|
Cephalexin_ddi.xml
|
DDI-DrugBank.d303.s3
|
DDI-DrugBank.d303.s3.p2
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
erythromycin
|
fluoxetine
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p198
|
Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.
|
phenytoin
|
doxycycline
|
MECHANISM
|
Doxycycline_ddi.xml
|
DDI-DrugBank.d500.s4
|
DDI-DrugBank.d500.s4.p5
|
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylurea
|
chloramphenicol
|
EFFECT
|
Chlorpropamide_ddi.xml
|
DDI-DrugBank.d245.s0
|
DDI-DrugBank.d245.s0.p3
|
- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired
|
Bezalip
|
anion-exchange resins
|
ADVISE
|
Bezafibrate_ddi.xml
|
DDI-DrugBank.d291.s9
|
DDI-DrugBank.d291.s9.p1
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.